拨康视云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE IN RELATION TO INVESTIGATIONAL NEW DRUG APPLICATION FOR CBT-009 SUCCESSFULLY SUBMITTED TO CENTER FOR DRUG EVALUATION

This announcement is made by Cloudbreak Pharma Inc. (the "**Company**") together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that ADS Therapeutics LLC ("**ADS USA**"), a wholly-owned subsidiary of the Company registered under the laws of Delaware, the United States of America (the "**USA**"), has successfully submitted the Investigational New Drug ("**IND**") application for CBT-009, one of the Group's core products, to the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration ("**NMPA**") of China.

As disclosed by the Company in its prospectus dated 24 June 2025, the interim report of the Group for the six months ended 30 June 2025 and the voluntary announcement dated 27 November 2025 in relation to business update:

CBT-009 is a novel, non-aqueous atropine ophthalmic formulation independently developed by the Group for the treatment of juvenile myopia in children and adolescents aged 5 to 19. Compared with existing aqueous atropine eye drops, CBT-009 offers significantly improved formulation stability, enabling long-term storage at room temperature without the need for preservatives, and substantially enhancing patient compliance and experience.

The Company considers the successful IND submission to CDE represents a critical milestone in the clinical development of CBT-009 in China, laying a solid foundation for the Group to advance Phase III clinical trials in this key market. The Group will continue to closely monitor the evaluation progress by CDE and make further announcement(s) to keep the shareholders and potential investors of the Company informed of the latest developments in this regard as and when appropriate.

Warning Statement: There is no guarantee that CBT-009 or any other Core Product of the Group will ultimately be successfully developed, launched or marketed.

Shareholders and potential investors of the Company should exercise caution and due care when dealing in the shares of the Company.

By order of the Board
Cloudbreak Pharma Inc.
Dr. NI Jinsong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 6 January 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van and Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter and Mr. Lee Alex Jao Jang as independent non-executive directors.

* *For identification purpose only*